Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Down 80.8% in August

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 127,301 shares, a decrease of 80.8% from the August 15th total of 661,820 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 724,767 shares, the short-interest ratio is presently 0.2 days.

Bayer Aktiengesellschaft Stock Down 0.9%

Shares of Bayer Aktiengesellschaft stock opened at $13.95 on Friday. The company has a quick ratio of 0.67, a current ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a market cap of $54.82 billion, a P/E ratio of -27.35, a PEG ratio of 2.11 and a beta of 0.56. The firm’s 50 day moving average price is $14.00 and its 200-day moving average price is $12.27. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.06. The firm had revenue of $12.53 billion for the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft had a positive return on equity of 16.77% and a negative net margin of 3.80%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.28 EPS for the current fiscal year.

Analyst Ratings Changes

BAYRY has been the topic of several recent analyst reports. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Finally, DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics.